OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Sprint Bioscience AB OCF Yield % Related Terms
Sprint Bioscience AB OCF Yield % Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB (OSTO:SPRINT) has a OCF Yield % of 15.01 as of Jul. 04, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Sprint Bioscience AB and its competitors. According to the industry distribution chart, Sprint Bioscience AB ranks #32 out of 1414 companies in the Biotechnology industry, placing it in the top 2.3%.
Is Sprint Bioscience AB's OCF Yield % too high?
Sprint Bioscience AB's current OCF Yield % is 15.01. Based on the distribution chart, Sprint Bioscience AB ranks #32 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #32 out of 1414 companies for OCF Yield %. This places Sprint Bioscience AB in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Sprint Bioscience AB and its competitors. Sprint Bioscience AB's current OCF Yield % is 15.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.07 — trading 86.7% above its estimated fair value. The current OCF Yield % is 15.01. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current OCF Yield % is 15.01 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?
Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued.
The current stock price of kr4.07 is trading 86.7% above its estimated GF Value™ of kr2.18.
GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPRINT:
OCF Yield %: 15.01
GF Value™: kr2.18 vs. price of kr4.07 (86.7% above fair value)
No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score
Get the complete analysis for OSTO:SPRINT
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
